Abstract
The development of new drugs has been greatly hampered in the field of lymphomas by many methodological problems, mainly related to the heavy pre-treatment of many patients. These methodological problems will be discussed. During the last years, however, a few interesting new compounds have emerged. The most exciting ones belong to the family of the purine-analogues, among them Fludarabine and 2-CdA (2-Chlorodeoxyadenosine) have been widely tested in many phase II trials. In selected series the response rate has approached 75–80% depending on the selection of the patients. Currently, phase II trials in previously untreated patients as well as randomized phase III trials are ongoing. Further developments in this area are represented by immunotoxins, ra-diolabelled monoclonal antibodies and tumour vaccines. Therapeutic possibilities as well as still existing methodological weaknesses of these approaches will be discussed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
